Comparative Pharmacology
Head-to-head clinical analysis: GANTRISIN PEDIATRIC versus LIPO GANTRISIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTRISIN PEDIATRIC versus LIPO GANTRISIN.
GANTRISIN PEDIATRIC vs LIPO GANTRISIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfisoxazole is a competitive inhibitor of bacterial dihydropteroate synthase, preventing the incorporation of para-aminobenzoic acid (PABA) into dihydrofolate, thereby inhibiting bacterial folic acid synthesis.
Lipo Gantrisin is a liposomal formulation of sulfisoxazole, a sulfonamide antibiotic. It inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby bacterial DNA replication.
2-4 g initially, then 4-6 g/day in 3-6 divided doses orally, depending on severity. Alternatively, for sulfisoxazole (the active moiety), typical adult dose is 500 mg to 1 g orally every 6 hours. IM use: 50 mg/kg initially, then 100 mg/kg/day in divided doses every 6-8 hours. IV use: Not recommended in pediatric formulation.
2-4 mL (80-160 mg sulfisoxazole equivalent) intramuscularly every 12 hours for 5-7 days.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours (prolonged in renal impairment; up to 30 hours in patients with creatinine clearance <10 mL/min).
The terminal elimination half-life is approximately 7-12 hours in adults with normal renal function; prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min). This necessitates dose adjustment in renal disease.
Primarily renal (70-100% as unchanged drug and acetylated metabolites) via glomerular filtration and tubular secretion; <10% fecal.
Lipo Gantrisin is excreted primarily renally (70-80%) as unchanged drug and its acetylated metabolite. Biliary/fecal elimination accounts for 20-30%, with enterohepatic recirculation present.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic